NANOOOOOOOO.Betalutin sammen med Truxima. Konsekvenser ?
The FDA has granted approval to the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy, making it the first biosimilar approved by the FDA for the treatment of patients with NHL.
Redigert 20.01.2021 kl 12:32
Du må logge inn for å svare
SafeInvest
30.11.2018 kl 21:07
2556
Dette er svært, nå kan Teva og Celltrion hive seg inn i kampen om Betalutin og Nano. Det tilspisser seg i non-Hodgkin lymphoma markedet
SafeInvest
30.11.2018 kl 23:01
2295
Men ikke forvent at dette får noen oppmerksomt i bakgården på Oslo børs
Frontmasta
30.11.2018 kl 23:47
2135
In a bid to place Korea on the biotech global map, the Korean government announced plans to will inject 500 billion won (US$448 million) into the pharmaceutical sector over the next 10 years, with the goal of producing some 100 new drugs by 2026. Under the plan announced by the Ministry of ICT and Science, South Korea aims to expand its presence in the global bio market from its current 1.7 percent to 5 percent by 2025.
Merlin
01.12.2018 kl 00:08
2076
This Drugmaker’s Value Surged $8 Billion In Just Seven Days
By Min Jeong Lee and Heejin Kim
10. januar 2018, 05:09 CET
The surge has seen Incheon-based Celltrion -- which makes most of its money manufacturing copies of drugs whose patents have expired -- streak past Hyundai Motor Co., South Korea’s largest automaker, to become the third-biggest company by value on the country’s stock exchange. Its 37 trillion won market cap puts it behind smartphone behemoth Samsung Electronics Co. at No. 1 and chip giant SK Hynix Inc. in second place.
The surge has seen Incheon-based Celltrion -- which makes most of its money manufacturing copies of drugs whose patents have expired -- streak past Hyundai Motor Co., South Korea’s largest automaker, to become the third-biggest company by value on the country’s stock exchange. Its 37 trillion won market cap puts it behind smartphone behemoth Samsung Electronics Co. at No. 1 and chip giant SK Hynix Inc. in second place.
In fact, SK Hynix’s 53 trillion-won market cap is now about equal to the combined value of Celltrion and its two subsidiaries Celltrion Healthcare Co. and Celltrion Pharm Inc.
https://www.bloomberg.com/news/articles/2018-01-10/drugmaker-s-8-billion-surge-in-a-week-rocks-korean-stock-market?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo
By Min Jeong Lee and Heejin Kim
10. januar 2018, 05:09 CET
The surge has seen Incheon-based Celltrion -- which makes most of its money manufacturing copies of drugs whose patents have expired -- streak past Hyundai Motor Co., South Korea’s largest automaker, to become the third-biggest company by value on the country’s stock exchange. Its 37 trillion won market cap puts it behind smartphone behemoth Samsung Electronics Co. at No. 1 and chip giant SK Hynix Inc. in second place.
The surge has seen Incheon-based Celltrion -- which makes most of its money manufacturing copies of drugs whose patents have expired -- streak past Hyundai Motor Co., South Korea’s largest automaker, to become the third-biggest company by value on the country’s stock exchange. Its 37 trillion won market cap puts it behind smartphone behemoth Samsung Electronics Co. at No. 1 and chip giant SK Hynix Inc. in second place.
In fact, SK Hynix’s 53 trillion-won market cap is now about equal to the combined value of Celltrion and its two subsidiaries Celltrion Healthcare Co. and Celltrion Pharm Inc.
https://www.bloomberg.com/news/articles/2018-01-10/drugmaker-s-8-billion-surge-in-a-week-rocks-korean-stock-market?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo